Recent Advancements in Pharmacogenomic Biomarkers for Asthma

Nayan Kuhikar; Karishma Duhijod; Mohini Thete; Kritika Channe

doi:10.52711/2321-5836.2026.00001

Research Journal of Pharmacology and Pharmacodynamics

ISSN

2321-5836 (Online)
0975-4407 (Print)

Submit Article

Recent Advancements in Pharmacogenomic Biomarkers for Asthma

Author(s): Nayan Kuhikar, Karishma Duhijod, Mohini Thete, Kritika Channe

Email(s): karishmaduhijod1@gmail.com

DOI: 10.52711/2321-5836.2026.00001

Address: Nayan Kuhikar, Karishma Duhijod*, Mohini Thete, Kritika Channe
1Nagpur College of Pharmacy, Hingna Road, Wanadongri, Nagpur 441110.
*Corresponding Author

Published In: Volume - 18, Issue - 1, Year - 2026

View HTML

Purchase PDF

ABSTRACT:
Asthma is a complex, heterogeneous respiratory disorder characterized by variable airflow obstruction, airway hyper responsiveness, and chronic inflammation. Despite advancements in therapeutic options, interindividual variability in drug response remains a significant challenge in asthma management. Pharmacogenomics, the study of how genetic variations influence drug efficacy and safety, has emerged as a promising approach to personalize asthma therapy. Recent research has identified critical pharmacogenomic biomarkers, including polymorphisms in genes such as ADRB2, GLCCI1, ALOX5, and IL4RA, which predict differential responses to ß2-agonists, inhaled corticosteroids, leukotriene modifiers, and biologic agents targeting type 2 inflammation pathways. Technological advancements, including genome-wide association studies (GWAS), next-generation sequencing (NGS), and multi-omics integration, have accelerated the discovery of novel biomarkers and refined asthma endotyping. Furthermore, the application of artificial intelligence and machine learning is enhancing biomarker discovery and predictive modeling. Despite promising developments, challenges such as population heterogeneity, ethical concerns, and limited clinical implementation persist. This review highlights the recent progress in pharmacogenomic biomarker discovery and their potential to transform asthma management into a more precise and individualized discipline.

Keywords:

Cite this article:
Nayan Kuhikar, Karishma Duhijod, Mohini Thete, Kritika Channe. Recent Advancements in Pharmacogenomic Biomarkers for Asthma. Research Journal of Pharmacology and Pharmacodynamics. 2026;18(1):1-6. doi: 10.52711/2321-5836.2026.00001

Cite(Electronic):
Nayan Kuhikar, Karishma Duhijod, Mohini Thete, Kritika Channe. Recent Advancements in Pharmacogenomic Biomarkers for Asthma. Research Journal of Pharmacology and Pharmacodynamics. 2026;18(1):1-6. doi: 10.52711/2321-5836.2026.00001 Available on: https://rjppd.org/AbstractView.aspx?PID=2026-18-1-1

REFERENCES:

1. Wang, T. N., Lin, M. C., Wu, C. C., and Huang, M. S. Pharmacogenomics and asthma treatment: A new era of precision medicine. International Journal of Molecular Sciences. 2020; 21(15): 5480.

2. Ortega, V. E., Meyers, D. A., and Bleecker, E. R. Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmacogenomics and Personalized Medicine. 2015; 8: 9–22.

3. Fitzpatrick, A. M., Teague, W. G., and Meyers, D. A. Asthma phenotypes and endotypes for precision medicine and targeted therapy. Journal of Allergy and Clinical Immunology. 2022; 149(2): 406–416.

4. Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., and Brightling, C. E. After asthma: Redefining airways diseases. The Lancet. 2018; 391(10118): 350–400.

5. Holgate, S. T., Wenzel, S., Postma, D. S., Weiss, S. T., Renz, H., and Sly, P. D. Asthma. Nature Reviews Disease Primers. 2015; 1(1): 15025.

6. Wenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet, J., Busse, W., Dahlen, S. E., and Ziegler, S. F. A systematic approach to severe asthma. Journal of Allergy and Clinical Immunology. 2012; 129(5): 946–958.

7. Fahy, J. V., Locksley, R. M. The airway epithelium as a regulator of Th2 responses in asthma. The Journal of Clinical Investigation. 2015; 125(3): 970–980.

8. Moffatt, M. F., Gut, I. G., Demenais, F., Strachan, D. P., Bouzigon, E., Heath, S., and Cookson, W. O. A large-scale, consortium-based genomewide association study of asthma. New England Journal of Medicine. 2010; 363(13): 1211–1221.

9. Demenais, F., Margaritte-Jeannin, P., Barnes, K. C., Cookson, W. O., Altmüller, J., Ang, W., and Moffatt, M. F. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nature Genetics. 2018; 50(1): 42–53.

10. Lappalainen, T., Sammeth, M., Friedländer, M. R., 't Hoen, P. A. C., Monlong, J., Rivas, M. A., and Dermitzakis, E. T. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2017; 501(7468): 506–511.

11. Tantisira, K. G., Lasky-Su, J., Harada, M., Murphy, A., and Litonjua, A. A. Genomewide association study of pharmacogenetic response to inhaled β2-agonists in asthma. Journal of Allergy and Clinical Immunology. 2011; 127(2): 530–537.

12. Hawkins, G. A., Tantisira, K., Meyers, D. A., and Lazarus, R. Pharmacogenetic studies of asthma: the times they are a-changin. Pharmacogenomics. 2012; 13(9): 1139–1148.

13. Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske Jr, R. F., and Boushey, H. A. Beta-agonist use and asthma control: The role of pharmacogenetic variation. Respiratory Research. 2009; 10: 108.

14. Klotsman, M., York, T. P., Pillai, S. G., Vargas-Irwin, C., and Ashley-Koch, A. Pharmacogenetics of asthma: a systematic review and meta-analysis. Human Genomics. 2007; 2(2).

15. Zhang, Y., Zheng, L., Guo, J., Zhuang, Q., and Wu, L. Genetic determinants of response to biologic treatments in asthma: Pharmacogenomics insights. Frontiers in Genetics. 2020; 11: 571047.

16. Sordillo, J. E., Kelly, R., Bunyavanich, S., McGeachie, M. J., and Gaffin, J. Multi-omics studies of childhood asthma: integrating the environment, genetics, and epigenetics. Journal of Allergy and Clinical Immunology. 2021; 147(3): 823–832.

17. Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske, R. F., Boushey, H. A., Deykin, A., and Israel, E. Beta-adrenergic receptor polymorphisms and response to salmeterol. American Journal of Respiratory and Critical Care Medicine. 2009; 179(4): 323–329.

18. Tantisira, K. G., Lake, S., Silverman, E. S., Palmer, L. J., Lazarus, R., Silverman, E. K., and Weiss, S. T. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Human Molecular Genetics. 2004; 13(13): 1353–1359.

19. Israel, E., et. al. The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. American Journal of Respiratory and Critical Care Medicine. 2000; 162(1): 75–80.

20. Drysdale, C. M., McGraw, D. W., Stack, C. B., Stephens, J. C., Judson, R. S., Nandabalan, K., Arnold, K., Ruano, G., and Liggett, S. B. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proceedings of the National Academy of Sciences. 2000; 97(19): 10483–10488.

21. Leung, D. Y., Hamid, Q., Vottero, A., Szefler, S. J., Surs, W., Minshall, E., Chrousos, G. P., and Klemm, D. J. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β. Journal of Experimental Medicine. 1997; 186(9): 1567–1574.

22. Tantisira, K. G., et. al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. New England Journal of Medicine. 2011; 365(13): 1173–1183.

23. Tantisira, K. G., Lasky-Su, J., Harada, M., Murphy, A., Litonjua, A. A., Himes, B. E., and Weiss, S. T. Genomewide association scan linked to lung function and clinical outcomes in asthma. New England Journal of Medicine. 2011; 363(13): 1210-1219.

24. Sampson, A. P., Green, C. P., Price, J. F., Yea, C. M., and Lee, T. H. Leukotriene and prostanoid pathways in asthma. Journal of Allergy and Clinical Immunology. 2000; 106(3): S97–S104.

25. Drazen, J. M., Yandava, C. N., Dube, L., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., and Schork, N. J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetics. 1999; 22(2): 168–170.

26. Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., Chanez, P., and Investigators of the DREAM Study. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine. 2014; 371(13): 1198–1207.

27. Hershey, G. K., Friedrich, M. F., Esswein, L. A., Thomas, M. L., and Chatila, T. A. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. New England Journal of Medicine. 1997; 337(24): 1720–1725.

28. Moffatt, M. F., et. al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007; 448(7152): 470–473.

29. Castro-Rodriguez, J. A., Forno, E., Celedón, J. C., and Gignoux, C. R. Asthma genetics and genomics 2020: New insights and future directions. Current Opinion in Pulmonary Medicine. 2020; 26(1): 36–42.

30. Yick, C. Y., Ferreira, D. S., Annunziato, F., and Barnes, P. J. Advances in asthma genetics and epigenetics: Pathogenesis to precision medicine. European Respiratory Review. 2021; 30(161): 210093.

31. Nicodemus-Johnson, J., Myers, R. A., Sakabe, N. J., Sobreira, D. R., Hogarth, D. K., Naureckas, E. T., and Ober, C. DNA methylation in lung cells is associated with asthma endotypes and genetic risk. The Journal of Allergy and Clinical Immunology. 2016; 138(6): 1836–1848.

32. Modena, B. D., Bleecker, E. R., Busse, W. W., Erzurum, S. C., Gaston, B. M., Jarjour, N. N., and Fahy, J. V. Gene expression correlated with severe asthma characteristics reveals heterogeneous mechanisms of severe disease. American Journal of Respiratory and Critical Care Medicine. 2017; 195(11): 1449–1463.

33. Vieira Braga, F. A., Kar, G., Berg, M., Carpaij, O. A., Polanski, K., Simon, L. M., ... and Teichmann, S. A. A cellular census of human lungs identifies novel cell states in health and asthma. Nature Medicine. 2019; 25(7): 1153–1163.

34. Jackson, D. J., Makrinioti, H., Rana, B. M. J., Shamji, B. W., Trujillo-Torralbo, M. B., Footitt, J., and Edwards, M. R. Single-cell analysis of airway cells in children with asthma reveals a shift toward innate immune responses. The Journal of Allergy and Clinical Immunology. 2020; 145(5): 1297–1307.

35. Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., and Ortega, H. G. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine. 2014; 371(13): 1189-1197.

36. Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., and Humbert, M. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine. 2014; 371(13): 1198-1207.

37. Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M., Geba, G. P., and Aziz, I. Targeting IL-5 or eosinophils for asthma treatment: biomarkers, blood eosinophils, and beyond. Journal of Allergy and Clinical Immunology. 2022; 149(3): 793-804.

38. Menzies-Gow, A., Corren, J., Bourdin, A., Chupp, G., Israel, E., Wechsler, M. E., and Colice, G. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. New England Journal of Medicine. 2021; 384(19): 1800-1809.

39. Tantisira, K. G., Lake, S., Silverman, E. S., Palmer, L. J., Lazarus, R., Silverman, E. K., and Weiss, S. T. Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Human Molecular Genetics. 2011; 13(13): 1353–1359.

40. Ortega, V. E., Meyers, D. A., and Bleecker, E. R. Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmacogenomics and Personalized Medicine. 2015; 8: 9–22.

41. Agache, I., Song, Y., Posso, M., Alonso-Coello, P., and Akdis, C. Biologicals for severe asthma: A systematic review and network meta-analysis. Allergy. 2022; 77(5): 1411-1422.

42. Wechsler, M. E., Kelley, J. M., Boyd, I. O., Dutile, S., Marigowda, G., Kirsch, I., and Kaptchuk, T. J. Personalized medicine and genetic approaches to asthma therapy. Current Opinion in Pulmonary Medicine. 2019; 25(1): 86–93.

43. Sharma, S., Guleria, R., Ghosh, B., and Aggarwal, A. N. Pharmacogenomics in asthma: Promises, challenges, and future directions. Frontiers in Pharmacology. 2021; 12: 638343.

44. Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R., and Ginsburg, G. S. Implementing genomic medicine in the clinic: The future is here. Genetics in Medicine. 2019; 21(4): 767–774.

45. Zhou, X., Qiu, Y., Zhao, P., and Li, Q. Integration of pharmacogenomics into clinical practice: Opportunities and challenges for asthma therapy. Frontiers in Genetics. 2021; 12: 655184.

46. Liao, K. P., Kurreeman, F., Li, G., Cui, J., Huang, J., Glass, R. J., and Plenge, R. M. Pharmacogenomics and its potential application in asthma and allergy therapy. Pharmacogenomics Journal. 2022; 22(2): 87–96.

47. FitzGerald, J. M., Lemiere, C., Lougheed, M. D., Ducharme, F. M., Dell, S. D., Ramsey, C., and Boulet, L. P. Severe asthma: Clinical management and research priorities. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2022; 6(2): 67-76.

48. Sundar, K. M., Soni, M., and Comellas, A. Application of machine learning in asthma management: Recent advances and future directions. Respiratory Research. 2023; 24(1): 89.

49. Zhao, J., Jiang, P., Zhang, Y., and Wang, Z. Machine learning-based integration of multi-omics data for the prediction of asthma severity. Frontiers in Genetics. 2021; 12: 678574.

50. Pividori, M., Schoettler, N., Nicolae, D. L., Ober, C., and Im, H. K. Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies. The Lancet Respiratory Medicine. 2019; 7(6): 509-522.

51. Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., and Teague, W. G. International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma. European Respiratory Journal. 2022; 59(6): 2102919.

52. Kauppi, P., Linna, M., Martikainen, J., and Haahtela, T. Digital health interventions and asthma self-management: Opportunities and challenges. Journal of Asthma and Allergy. 2023; 16: 279–292.